William H.. Dunn Jr's Net Worth
Who is William H.. Dunn Jr? William H.. Dunn Jr does not have any significant net worth to report based on the numbers we have. This is based on reported shares in PROTHENA CORP PUBLIC LTD CO.
Model output · Signal date 2026-10-14
Prothena Corp Public Ltd Co (PRTA) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Alpha
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Middle 30%
of 5379 stocks scored
Rank correlation · 90D
n/a
No per-ticker sample yet
Market Cap
$429M
small-cap · #60 of 60 peers
Summary
Prothena Corp Public Ltd Co (PRTA) stock forecast summary
On Oct. 14, 2026, PRTA is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Prothena Corp Public Ltd Co is a small-cap company with a market capitalization of $429M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its P/B Ratio of 1.50x is the lowest of the 43 peers that report one.
A per-ticker accuracy statistic for PRTA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PRTA included.
Follow PRTA freePrice
PRTA price chart and AI forecast
Cross-section · 2026-10-13
How PRTA ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals
Prothena Corp Public Ltd Co (PRTA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | PRTA | Rank |
|---|---|---|
| Market Cap | $429M | 60/60 |
| P/B Ratio | 1.50x | 43/43 |
| EPS | $-1.43 | – |
| Book Value/Share | $5.59 | – |
| Revenue/Share | $1.12 | – |
Profitability & Margins
| Metric | PRTA | Rank |
|---|---|---|
| ROE | -15.3% | 21/33 |
| ROA | -14.5% | 25/39 |
| ROIC | -19.1% | 28/41 |
| Operating Margin | -96.8% | 28/33 |
| Net Margin | -76.7% | 25/33 |
| EBT Margin | -77.3% | 33/40 |
| Tax Rate | 0.8% | – |
Financial Health
| Metric | PRTA | Rank |
|---|---|---|
| Current Ratio | 25.05x | 5/50 |
| D/E Ratio | 0.05x | 37/43 |
| Financial Leverage | 1.05x | 37/43 |
| Interest Coverage | -8.3x | 24/36 |
| Working Capital | $280M | 45/50 |
Cash Flow
| Metric | PRTA | Rank |
|---|---|---|
| Operating Cash Flow | -$60M | 31/49 |
Operational Efficiency
| Metric | PRTA | Rank |
|---|---|---|
| Asset Turnover | 0.19x | 32/38 |
| Fixed Assets Turnover | 23.1x | 11/37 |
Income Statement
| Metric | PRTA | Rank |
|---|---|---|
| Total Revenue | $57M | 38/39 |
| Operating Income | -$55M | 22/41 |
| Net Income | -$43M | 22/40 |
| R&D Expense | $65M | 45/48 |
Dividend & Shareholder Information
| Metric | PRTA | Rank |
|---|---|---|
| Shares Outstanding | 51M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $292M | 96.8% of assets |
| Cash & Short-term Investments | $288M | 95.5% of assets |
| Total Liabilities | $16M | 5.2% of assets |
| Short-term Debt | $10M | 3.2% of assets |
Quarterly Financial Reports
PRTA quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Prothena Corp Public Ltd Co (PRTA) industry peers
Companies classified under the same SEC industry code as Prothena Corp Public Ltd Co (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| PRTA Prothena Corp Public Ltd Co | ▶ | $429M |
| LLY Eli Lilly & Co | ▲ | $1.10T |
| JNJ Johnson & Johnson | ▼ | $599.12B |
| ONC Beone Medicines Ltd. | ▶ | $515.98B |
| ABBV Abbvie Inc. | ▼ | $484.61B |
| MRK Merck & Co., Inc. | ▼ | $350.29B |
| NVS Novartis Ag | ▼ | $271.74B |
| GSK Gsk Plc | ▼ | $199.68B |
| ABT Abbott Laboratories | ▶ | $178.85B |
| PFE Pfizer Inc | ▲ | $161.70B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $128.50B |
| BMY Bristol Myers Squibb Co | ▼ | $115.76B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $77.54B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $48.07B |
| SNY Sanofi | ▼ | $47.70B |
| RPRX Royalty Pharma Plc | ▲ | $32.53B |
| ZTS Zoetis Inc. | ▼ | $31.26B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $29.95B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $29.46B |
| ZLAB Zai Lab Ltd | ▼ | $27.60B |
| ATHE Alterity Therapeutics Ltd | ▶ | $26.74B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.09B |
| UTHR United Therapeutics Corp | ▼ | $23.59B |
| INSM Insmed Inc | ▶ | $21.14B |
| VTRS Viatris Inc | ▶ | $20.15B |
| ASND Ascendis Pharma A/S | ▶ | $13.83B |
| SMMT Summit Therapeutics Inc. | ▶ | $13.67B |
| JAZZ Jazz Pharmaceuticals Plc | ▶ | $13.66B |
| CORT Corcept Therapeutics Inc | ▲ | $12.73B |
| BBIO Bridgebio Pharma, Inc. | ▲ | $12.37B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.25B |
| HCM Hutchmed (China) Ltd | ▶ | $11.78B |
| ELAN Elanco Animal Health Inc | ▶ | $11.20B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.66B |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.53B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.45B |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.96B |
| CYTK Cytokinetics Inc | ▶ | $8.57B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.21B |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.19B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.09B |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.04B |
| ABVX Abivax S.A. | ▼ | $6.83B |
| PRAX Praxis Precision Medicines, Inc. | ▶ | $6.79B |
| ALKS Alkermes Plc. | ▶ | $6.67B |
| LEGN Legend Biotech Corp | ▶ | $6.61B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.25B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $6.05B |
| BLTE Belite Bio, Inc | ▲ | $5.97B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.96B |
| BLRX Biolinerx Ltd. | ▶ | $5.67B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.17B |
| ERAS Erasca, Inc. | ▲ | $5.17B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.00B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.88B |
| COGT Cogent Biosciences, Inc. | ▼ | $4.87B |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.86B |
| MANE Veradermics, Inc | ▲ | $4.86B |
| GPCR Structure Therapeutics Inc. | ▲ | $4.77B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.34B |
Where PRTA sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Prothena Corp Public Ltd Co (PRTA) stock news
Un initié de Prothena Corp Public Ltd a acheté des actions pour 857 240 dollars, selon un récent dépôt auprès de la SEC
William P. Scully, actionnaire détenant 10 % du capital, a acheté le 2 octobre 2026 100 000 actions de Prothena Corp Public Ltd pour un montant de 857 240 dollars. À la suite du dépôt ...
Prothena Corp Public Ltd : un initié a acheté des actions pour 889 872 dollars, selon un récent dépôt auprès de la Securities and Exchange Commission (SEC)
William P. Scully, détenteur de 10 % du capital, a acheté le 28 septembre 2026 103 500 actions de Prothena Corp Public Ltd pour 889 872 dollars. Selon le dépôt du formulaire 4 auprès de ...
FAQ
Prothena Corp Public Ltd Co (PRTA) stock forecast FAQ
What is the Prothena Corp Public Ltd Co (PRTA) stock forecast?
On Oct. 14, 2026, PRTA is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Prothena Corp Public Ltd Co stock predictions?
A per-ticker accuracy statistic for PRTA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Prothena Corp Public Ltd Co forecasts updated?
Prothena Corp Public Ltd Co forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Prothena Corp Public Ltd Co's industry peers?
60 issuers in our coverage, PRTA included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Beone Medicines Ltd. (ONC), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.